Peptide News Digest

Gilead Hepcludex Bulevirtide FDA Approval — First HDV Treatment, Altimmune Pemvidutide EASL 2026, Madrigal Rezdiffra Portal Hypertension Data, Umbrella Labs Epitalon

Gilead's Hepcludex (bulevirtide) FDA accelerated approval — first US treatment for chronic HDV, Altimmune pemvidutide EASL fibrosis regression, Madrigal Rezdiffra portal hypertension.

6 stories · Covering regulatory, clinical-trials, industry, research

Editor's Note

Memorial Day Monday digest is light on US news flow given the federal holiday, but the Friday before delivered the biggest non-GLP-1 peptide regulatory event of 2026 to date. The FDA granted accelerated approval on May 22 to Gilead's Hepcludex (bulevirtide-gmod) 8.5 mg, the first and only US-approved treatment for chronic hepatitis delta virus (HDV) infection. Bulevirtide is a 47-amino acid N-terminally myristoylated lipopeptide that acts as an entry inhibitor by binding to the sodium taurocholate cotransporting polypeptide (NTCP) — the receptor HDV and HBV both use to enter hepatocytes. The Phase 3 MYR301 trial supported the approval on a combined virologic and biochemical response endpoint at week 48; continued approval depends on a confirmatory trial. EASL 2026 in Barcelona opens Wednesday May 27 with a peptide-MASH slate that includes Altimmune's pemvidutide (GLP-1/glucagon dual peptide) IMPACT Phase 2b oral and late-breaking fibrosis-regression poster — both the AI-based Liver Explore quantitative pathology data and the non-invasive PRO-C3:CTX-III ratio support fibrosis regression at 24 weeks. Madrigal Pharmaceuticals previewed Rezdiffra EASL data on cardiovascular and portal-hypertension markers from MAESTRO-NASH plus MAESTRO-NAFLD-1 secondary analyses — building the case for the only FDA-approved MASH therapy beyond the F2-F3 noncirrhotic-MASH indication into compensated MASH cirrhosis. Umbrella Labs published a documentation and traceability update Monday for Epitalon peptide reference material, the same template the company used May 19 for Dihexa — reference-material standardization ahead of Epitalon's July 23-24 PCAC review. The thin US news cycle reflects the federal holiday; EASL plus ASCO 2026 land back-to-back this week and Tuesday's ASCO embargoed press briefing kicks the cycle back on.

Regulatory

Gilead Hepcludex (Bulevirtide-gmod) FDA Accelerated Approval (May 22): First and Only US Treatment for Chronic Hepatitis Delta Virus, 47-Amino-Acid Lipopeptide NTCP Entry Inhibitor

The FDA granted accelerated approval on May 22, 2026 to Gilead Sciences' Hepcludex (bulevirtide-gmod) 8.5 mg, the first and only approved US treatment for adults living with chronic hepatitis delta virus (HDV) infection. Bulevirtide — formerly known as Myrcludex B — is a 47-amino acid, N-terminally myristoylated lipopeptide derived from the pre-S1 domain of the HBV large envelope protein. The molecule binds to the sodium taurocholate cotransporting polypeptide (NTCP) — the entry receptor that HDV and HBV both use to enter hepatocytes — and blocks viral entry as a first-in-class entry inhibitor. The Phase 3 MYR301 trial documented a statistically significant combined virologic and biochemical response at week 48 versus delayed-treatment control, supporting the accelerated-approval threshold. Continued approval depends on confirmatory trial verification of clinical benefit. Bulevirtide has been EU-approved under conditional marketing authorization since 2020. Gilead shares closed Friday at $134.36, up roughly 3%.

#gilead-sciences #hepcludex #bulevirtide #hdv #lipopeptide #ntcp #fda-accelerated-approval #entry-inhibitor
Clinical Trials

Altimmune Pemvidutide EASL 2026 IMPACT Phase 2b — Late-Breaking Fibrosis Regression Poster Wednesday May 27 in MASH

Altimmune presents IMPACT Phase 2b clinical trial data on pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) at the European Association for the Study of the Liver Congress 2026 (May 27-30 Barcelona). The randomized, placebo-controlled, double-blind Phase 2b trial enrolled 212 biopsy-confirmed MASH patients with fibrosis stages F2 or F3 (with and without diabetes), randomized 1:2:2 to weekly subcutaneous pemvidutide 1.2 mg, 1.8 mg, or placebo for 48 weeks. The late-breaking poster Wednesday May 27 at 08:30 CEST reports the AI-based Liver Explore quantitative digital pathology analysis showing significant reductions in proportionate areas of early, advanced, and total liver fibrosis at 24 weeks. The non-invasive PRO-C3:CTX-III ratio reduced consistent with fibrosis regression. Pemvidutide is a GLP-1/glucagon dual-action peptide with FDA Fast Track designation for MASH plus Breakthrough Therapy Designation. The approach competes directly with Boehringer Ingelheim's survodutide and Eli Lilly's retatrutide on the GLP-1/glucagon arm for MASH.

#altimmune #pemvidutide #easl-2026 #mash #impact-trial #glp-1-glucagon #fibrosis-regression #liver-explore
Industry

Madrigal Rezdiffra EASL 2026 (May 20 Announcement): Cardiovascular and Portal Hypertension Risk Marker Data from MAESTRO-NASH + MAESTRO-NAFLD-1 Secondary Analyses

Madrigal Pharmaceuticals announced May 20 that multiple abstracts from its Rezdiffra (resmetirom) development and real-world evidence programs will be presented at EASL 2026 in Barcelona. Headline analyses include cardiovascular risk markers — secondary analysis of Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 examining improvements in Lp(a), LDL-C, and ApoB — and portal hypertension risk improvement in compensated MASH cirrhosis (F4c) measured by ANTICIPATE-NASH risk scores. Real-world evidence and noninvasive biomarker analyses round out the slate. Rezdiffra (a thyroid hormone receptor β agonist, not a peptide) was approved March 2024 as the first FDA-approved MASH therapy for noncirrhotic MASH with F2-F3 fibrosis. The EASL data extend the case toward compensated MASH cirrhosis and cardiovascular outcomes — a competitive context for the GLP-1/glucagon peptide programs (semaglutide ESSENCE, pemvidutide IMPACT, survodutide SYNCHRONIZE-1, retatrutide MASLD Phase 3) running on parallel tracks.

#madrigal-pharmaceuticals #rezdiffra #resmetirom #easl-2026 #mash #portal-hypertension #cardiovascular-risk
Industry

Umbrella Labs Epitalon Peptide Documentation Update (May 25): Reference-Material Standardization for Research Pipeline Ahead of July 23-24 PCAC Review

Umbrella Labs announced Monday May 25 a documentation and traceability update for its Epitalon peptide reference material, provided strictly for laboratory developmental research use. The update is part of the company's standardization initiative focused on identity-field consistency, record continuity, and reproducibility — the same template Umbrella applied to Dihexa on May 19. Epitalon (Glu-Asp-Gly-Lys) is a four-amino-acid peptide originally derived from the bovine pineal gland by Vladimir Khavinson and studied as a senescent-cell modulator and telomerase activator. The peptide is on the FDA's PCAC review docket for July 23-24, 2026 — Day 2 alongside Emideltide/DSIP and Semax — for potential 503A bulks-list inclusion. Reference-material standardization across the research-peptide supply chain is the soft regulatory signal that compounding pharmacies and supply networks are preparing for the PCAC review window.

#umbrella-labs #epitalon #reference-material #research-peptides #pcac #july-2026 #traceability
Industry

Memorial Day Monday US News Vacuum — EASL Tuesday May 26 ASCO Embargo, EASL Wednesday May 27 Opens

Monday May 25 is the US Memorial Day federal holiday; SEC filings, FDA actions, US company press releases pause for the day. The week's news cycle picks up Tuesday with ASCO's embargoed virtual press briefing for credentialed media (a preview of Late-Breaking Abstracts ahead of the May 29 Annual Meeting opening in Chicago) and Wednesday with EASL 2026's opening in Barcelona. The combined Tuesday-Wednesday cycle delivers the most concentrated peptide-mechanism data of any week in 2026 — Altimmune pemvidutide IMPACT MASH, Novo Nordisk ESSENCE liver safety, Madrigal Rezdiffra portal hypertension data, Eli Lilly retatrutide MASLD Phase 3 status, and Boehringer survodutide SYNCHRONIZE-1 preview at EASL plus the peptide-oncology cohort at ASCO (Bicycle, Avacta, BriaCell, BioVaxys, Crinetics, Sapience, Corbus). The Hepcludex approval Friday plus the EASL plus ASCO double-meeting structure makes this the highest-volume peptide-news week of 2026 to date.

#memorial-day #easl-2026 #asco-2026 #may-26-embargo #may-27-opening #peptide-meeting-week
Research

Hepcludex Mechanism Deep-Dive: Why a Lipopeptide Entry Inhibitor Cures What Antivirals Couldn't — NTCP Receptor Biology and the HBV/HDV Dependency

Bulevirtide's mechanism reveals why an entry inhibitor succeeded where small-molecule antivirals didn't. HDV is an obligate parasite of HBV — the delta virus uses the HBV envelope to assemble its virions and the HBV-derived large surface protein to enter hepatocytes via the sodium taurocholate cotransporting polypeptide (NTCP) receptor on hepatocyte cell membranes. Existing HBV antiviral nucleoside/nucleotide analogs (entecavir, tenofovir) suppress HBV replication but don't clear circulating HBsAg or interrupt the HDV entry cycle. Bulevirtide's 47-amino acid sequence — derived from the HBV pre-S1 domain — binds NTCP competitively and blocks both HDV and HBV entry. Real-world EU experience since 2020 shows roughly 50-60% of HDV patients achieve undetectable HDV RNA after 96 weeks of treatment, with a favorable safety profile dominated by injection-site reactions. The US approval expands access for an estimated 75,000-100,000 US patients with chronic HDV, most of whom were previously treated empirically with off-label interferon alfa with poor tolerability.

#bulevirtide #hepcludex #ntcp #hdv #hbv #lipopeptide-mechanism #entry-inhibitor #viral-hepatology